The value of MRD testing in multiple myeloma

Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value of minimal residual disease (MRD) monitoring in multiple myeloma (MM) as a potential new end-point in MM clinical trials, and as a marker of therapeutic response.